Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 3/20 | 0.67 |
| ▸ | GLA | P06280 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | NQO2 | P16083 | 2/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.53 |
| ▸ | CCND1 | P24385 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30634405 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1RXFP1GAAGLA | |
| SCHEMBL12002193 | 0.88 | KDM4E (0.78) | KDM4EALDH1A1RXFP1GAAGLA | |
| SCHEMBL2798566 | 0.86 | KDM4E (0.75) | KDM4EALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL30283738 | 0.83 | KDM4E (0.70) | KDM4EALDH1A1RXFP1GAAGLA | |
| SCHEMBL30283860 | 0.83 | KDM4E (0.71) | KDM4EALDH1A1RXFP1GAAGLA | |
| SCHEMBL28445737 | 0.83 | KDM4E (0.71) | KDM4EALDH1A1RXFP1GAAGLA | |
| SCHEMBL743131 | 0.83 | KDM4E (0.71) | KDM4EALDH1A1RXFP1GAAGLA | |
| SCHEMBL12667324 | 0.81 | KDM4E (0.69) | KDM4EALDH1A1RXFP1GAAGLA | |
| SCHEMBL12986903 | 0.80 | KDM4E (1.00) | KDM4EALDH1A1RXFP1GAAGLA | |
| SCHEMBL10285854 | 0.79 | KDM4E (0.65) | KDM4EALDH1A1GAAGLAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408863-B1 | NUCLEIC ACID BINDING DYES AND USES THEREFOR | PROMEGA CORP (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9458499-B2 | Nucleic acid binding dyes and uses therefor | PROMEGA CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458499-B2 | Nucleic acid binding dyes and uses therefor | PROMEGA CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160083782-A1 | NUCLEIC ACID BINDING DYES AND USES THEREFOR | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2016-03-24 | — | — | US | disclosed |
| US-20160083782-A1 | NUCLEIC ACID BINDING DYES AND USES THEREFOR | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2016-03-24 | — | — | US | disclosed |
| US-9206474-B2 | Nucleic acid binding dyes and uses therefor | PROMEGA CORPORATION (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206474-B2 | Nucleic acid binding dyes and uses therefor | PROMEGA CORPORATION (US) | 2015-12-08 | — | — | US | disclosed |
| US-8952010-B2 | Amino group-containing pyrrolidinone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| US-8952010-B2 | Amino group-containing pyrrolidinone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| US-8952010-B2 | Amino group-containing pyrrolidinone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20100233710-A1 | NUCLEIC ACID BINDING DYES AND USES THEREFOR | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2010-09-16 | — | — | US | disclosed |
| US-20100233710-A1 | NUCLEIC ACID BINDING DYES AND USES THEREFOR | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2010-09-16 | — | — | US | disclosed |
| US-20100233710-A1 | NUCLEIC ACID BINDING DYES AND USES THEREFOR | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2010-09-16 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
| US-5410054-A | Heteroaryl quinolines as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA, INC. (CA) | 1995-04-25 | — | — | US | disclosed |
| WO-1995003300-A1 | HETEROARYL QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1995-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233710-A1 | NUCLEIC ACID BINDING DYES AND USES THEREFOR | POLRMT, POLB, POLL | KDM4E 4619/4885ALDH1A1 898/4885RXFP1 3442/4885 |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | KDM4E 2360/4885ALDH1A1 2925/4885RXFP1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.